NEOS THERAPEUTICS,INC. (NASDAQ:NEOS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January29, 2019, the Board of Directors (the “Board”) of Neos Therapeutics,Inc. (the “Company”) unanimously appointed James Robinson to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from seven (7)directors to eight (8)directors. Upon his appointment to the Board, Mr.Robinson became a member of the class of directors with terms expiring at the 2019 Annual Meeting of Stockholders of the Company. The Board has determined that Mr.Robinson qualifies as an independent director and is qualified to serve under the applicable rulesand regulations of the Securities and Exchange Commission (the “SEC”) and the listing rulesof the Nasdaq Stock Market LLC. Mr.Robinson will serve as a member of the Company’s Compensation Committee. For his service on the Board, Mr.Robinson will receive the same compensation as other non-management directors, as described in the Company’s most recent proxy statement filed with the SEC. Mr.Robinson has also entered into the Company’s standard form of indemnification agreement.
Mr.Robinson, age 49, has been the President and Chief Operating Officer at Alkermes,Inc. since March2018. Prior to that, Mr.Robinson served as President, Americas Operations for Astellas US LLC (“Astellas”), a U.S. affiliate of Astellas Pharma Inc., a pharmaceutical company headquartered in Japan, from April2016 through February2018. From April2013 until March2016, Mr.Robinson served as President for Astellas Pharma US, which is responsible for Astellas’ commercial organization in the United States. In addition, Mr.Robinson served on the board of directors of Pharmaceutical Research and Manufacturers of America from 2013 to March2018. Mr.Robinson received his B.S. degree in marketing from DePaul University.
There are no arrangements or understandings between Mr.Robinson and any other persons to which he was elected as a director of the Company. There are no family relationships between Mr.Robinson and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed to Item 404(a)of Regulation S-K. Mr.Robinson is qualified to serve on the Board based on his leadership experience serving in executive level positions at various companies in the pharmaceutical industry.
About NEOS THERAPEUTICS,INC. (NASDAQ:NEOS)
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.